Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Matinas Biopharma Hl (MTNB)

Matinas Biopharma Hl (MTNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 10, 2023

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 265.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

MTNB : 0.1900 (-1.04%)
NOTV : 4.70 (-13.28%)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates Zacks - Wed Nov 2, 2022

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

MTNB : 0.1900 (-1.04%)
CNCE : 8.37 (+0.12%)
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Globe Newswire - Thu Aug 11, 2022

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility...

MTNB : 0.1900 (-1.04%)
Matinas BioPharma to Participate in the BTIG Biotechnology Conference Globe Newswire - Mon Aug 1, 2022

BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1900 (-1.04%)
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022 Globe Newswire - Thu Jul 28, 2022

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical...

MTNB : 0.1900 (-1.04%)
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis Globe Newswire - Mon Jul 25, 2022

BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1900 (-1.04%)
BTIG Remains a Buy on Matinas BioPharma (MTNB) TipRanks - Thu Jul 14, 2022

BTIG analyst Robert Hazlett reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report) on July 12 and set a price target of $3.00. The company's shares closed last Wednesday at $0.82. According...

MTNB : 0.1900 (-1.04%)
Matinas BioPharma to Present at the LD Micro Invitational XII Conference Globe Newswire - Tue May 31, 2022

BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving...

MTNB : 0.1900 (-1.04%)
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 12, 2022

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

MTNB : 0.1900 (-1.04%)
PRPH : 5.44 (-13.24%)
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights Globe Newswire - Thu May 12, 2022

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas’ proprietary LNC platform technology – ...

MTNB : 0.1900 (-1.04%)

Barchart Exclusives

3 Energy Dividend Stocks Leading the S&P 500 Higher Barchart - Thu Apr 18, 6:30PM CDT
These three energy dividend stocks have outperformed the S&P 500 on a year-to-date basis, and rank among the index's top 20 performers of 2024 so far. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot